Trials / Terminated
TerminatedNCT00750919
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)
A Twenty-six Weeks, Open-label Extension Trial to Evaluate Safety and Efficacy of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia Who Completed Clinical Trial Protocol 21106
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 184 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a 26-week, open label extension trial to investigate safety and explore efficacy of esmertazapine in participants with insomnia who completed protocol 21106/P05701/MK-8265-002 (NCT00631657).
Conditions
- Sleep Initiation and Maintenance Disorders
- Mental Disorders
- Dyssomnias
- Sleep Disorders
- Sleep Disorders, Intrinsic
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | esmirtazapine |
Timeline
- Start date
- 2008-10-07
- Primary completion
- 2010-03-10
- Completion
- 2010-03-10
- First posted
- 2008-09-11
- Last updated
- 2021-02-02
- Results posted
- 2014-06-24
Source: ClinicalTrials.gov record NCT00750919. Inclusion in this directory is not an endorsement.